|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Manfredi S, Lepage C, Hatem C, Coatmeur O,
Faivre J and Bouvier AM: Epidemiology and management of liver
metastases from colorectal cancer. Ann Surg. 244:254–259. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu
M, Shao R, Anderson RM, Rich JN and Wang XF: Periostin potently
promotes metastatic growth of colon cancer by augmenting cell
survival via the Akt/PKB pathway. Cancer Cell. 5:329–339. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yi HJ, Hong KS, Moon N, Chung SS, Lee RA
and Kim KH: Acute hyperammonemic encephalopathy after
5-fluorouracil based chemotherapy. Ann Surg Treat Res. 19:264–271.
2006.
|
|
5
|
Fuchs D, Metzig M, Bickeböller M, Brandel
C and Roth W: The Gβ5 protein regulates sensitivity to
TRAIL-induced cell death in colon carcinoma. Oncogene.
34:2753–2763. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hwang JS, Lee HC, Oh SC, Lee DH and Kwon
KH: Shogaol overcomes TRAIL resistance in colon cancer cells via
inhibiting of survivin. Tumour Biol. 36:8819–8829. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Laussmann MA, Passante E, Hellwig CT,
Tomiczek B, Flanagan L, Prehn JH, Huber HJ and Rehm M: Proteasome
inhibition can impair caspase-8 activation upon submaximal
stimulation of apoptotic tumor necrosis factor-related apoptosis
inducing ligand (TRAIL) signaling. J Biol Chem. 287:14402–14411.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Walczak H, Miller RE, Ariail K, Gliniak B,
Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al:
Tumoricidal activity of tumor necrosis factor-related
apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thorburn A, Behbakht K and Ford H: TRAIL
receptor-targeted therapeutics: Resistance mechanisms and
strategies to avoid them. Drug Resist Updat. 11:17–24. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Finlay D, Vamos M, González-López M,
Ardecky RJ, Ganji SR, Yuan H, Su Y, Cooley TR, Hauser CT, Welsh K,
et al: Small-molecule IAP antagonists sensitize cancer cells to
TRAIL-induced apoptosis: Roles of XIAP and cIAPs. Mol Cancer Ther.
13:5–15. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993.
|
|
12
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He H, Tian W, Chen H and Jiang K: MiR-944
functions as a novel oncogene and regulates the chemoresistance in
breast cancer. Tumour Biol. 37:1599–1607. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng Y, Lv X, Wang X, Wang B, Shao X,
Huang Y, Shi L, Chen Z, Huang J and Huang P: MiR-181b promotes
chemoresistance in breast cancer by regulating Bim expression.
Oncol Rep. 35:683–690. 2016.PubMed/NCBI
|
|
15
|
Kim AD, Zhang R, Han X, Kang KA, Piao MJ,
Maeng YH, Chang WY and Hyun JW: Involvement of glutathione and
glutathione metabolizing enzymes in human colorectal cancer cell
lines and tissues. Mol Med Rep. 12:4314–4319. 2015.PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yeh CC, Deng YT, Sha DY, Hsiao M and Kuo
MY: Suberoylanilide hydroxamic acid sensitizes human oral cancer
cells to TRAIL-induced apoptosis through increase DR5 expression.
Mol Cancer Ther. 8:2718–2725. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yin XM: Bid, a BH3-only multi-functional
molecule, is at the cross road of life and death. Gene. 369:7–19.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kantari C and Walczak H: Caspase-8 and
bid: Caught in the act between death receptors and mitochondria.
Biochim Biophys Acta. 1813:558–563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Frixa T, Donzelli S and Blandino G:
Oncogenic MicroRNAs: Key players in malignant transformation.
Cancers (Basel). 7:2466–2485. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ye Z, Hao R, Cai Y, Wang X and Huang G:
Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by
targeting the BIM-Bax/Bak axis in breast cancer. Tumour Biol.
37:4509–4515. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xie X, Hu Y, Xu L, Fu Y, Tu J, Zhao H,
Zhang S, Hong R and Gu X: The role of
miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance
and therapy in human breast cancer. Tumour Biol. 36:7185–7194.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu T, Jing C, Shi Y, Miao R, Peng L, Kong
S, Ma Y and Li L: microRNA-20a enhances the
epithelial-to-mesenchymal transition of colorectal cancer cells by
modulating matrix metalloproteinases. Exp Ther Med. 10:683–688.
2015.PubMed/NCBI
|
|
24
|
Babu KR and Muckenthaler MU: miR-20a
regulates expression of the iron exporter ferroportin in lung
cancer. J Mol Med (Berl). 94:347–359. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Salvesen GS and Walsh CM: Functions of
caspase 8: The identified and the mysterious. Semin Immunol.
26:246–252. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li H, Zhu H, Xu CJ and Yuan J: Cleavage of
BID by caspase 8 mediates the mitochondrial damage in the Fas
pathway of apoptosis. Cell. 94:491–501. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fulda S and Debatin KM: Extrinsic versus
intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene.
25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Billen LP, Shamas-Din A and Andrews DW:
Bid: A Bax-like BH3 protein. Oncogene. 27:(Suppl 1). S93–S104.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Orzechowska EJ, Girstun A, Staron K and
Trzcinska-Danielewicz J: Synergy of BID with doxorubicin in the
killing of cancer cells. Oncol Rep. 33:2143–2150. 2015.PubMed/NCBI
|
|
30
|
Eskes R, Desagher S, Antonsson B and
Martinou JC: Bid induces the oligomerization and insertion of Bax
into the outer mitochondrial membrane. Mol Cell Biol. 20:929–935.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wei MC, Lindsten T, Mootha VK, Weiler S,
Gross A, Ashiya M, Thompson CB and Korsmeyer SJ: tBID, a
membrane-targeted death ligand, oligomerizes BAK to release
cytochrome c. Genes Dev. 14:2060–2071. 2000.PubMed/NCBI
|
|
32
|
Billard C: Design of novel BH3 mimetics
for the treatment of chronic lymphocytic leukemia. Leukemia.
26:2032–2038. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Boonyarat C, Yenjai C, Vajragupta O and
Waiwut P: Heptaphylline induces apoptosis in human colon
adenocarcinoma cells through bid and Akt/NF-κB (p65) pathways.
Asian Pac J Cancer Prev. 15:10483–10487. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu CS, Chen GS, Lin PY, Pan IH, Wang ST,
Lin SH, Yu HS and Lin CC: Tazarotene induces apoptosis in human
basal cell carcinoma via activation of caspase-8/t-Bid and the
reactive oxygen species-dependent mitochondrial pathway. DNA Cell
Biol. 33:652–666. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Saelens X, Festjens N, Walle L Vande, van
Gurp M, van Loo G and Vandenabeele P: Toxic proteins released from
mitochondria in cell death. Oncogene. 23:2861–2874. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Trivedi R and Mishra DP: Trailing TRAIL
resistance: Novel targets for TRAIL sensitization in cancer cells.
Front Oncol. 5:692015. View Article : Google Scholar : PubMed/NCBI
|
